Last reviewed · How we verify
NCT05466019
A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)
Phase 2 trial testing Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU) in PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer in 30 participants. Status unknown.
1 May 2024
Quick facts
| Lead sponsor | The First Hospital of Jilin University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 May 2021 |
| Primary completion | 1 May 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU) — full drug profile →
Conditions studied
- PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer — all drugs for PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer →
Sponsor
The First Hospital of Jilin University
Who can join
Adults 18 to 75, any sex, with PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, patients with PD-L1 positive locally advanced patients with resectable gastric cancer or gastroesophageal junction adenocarcinoma were invited to participate in the study.To evaluate the efficacy and safety of patients with PD-L1 positive gastric cancer or gastroesophageal junction adenocarcinoma (≥T3 and the number of lymph node metastasis ≥1, and No distant metastasis) using Toripalimab combined with docetaxel, oxaliplatin, fluorouracil, leucovorin (FLOT regimen) .
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05466019
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The First Hospital of Jilin University trials
Trials by the same sponsor.
- NCT07308340 — Rapid Identification of Infectious Pathogens in Severe Pneumonia Guided by Bronchoscopic Imaging and Lung CT · not yet recruiting
- NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
- NCT07414160 — Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients · not yet recruiting
- NCT07440368 — Enterocyte Injury and Acute Gastrointestinal Dysfunction in Critical Illness · not yet recruiting
- NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05466019 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Hospital of Jilin University
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05466019.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing